All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.

Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to close in the coming days.

Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings could close as soon as Monday. The US Federal Trade Commission doesn't appear to have concerns about the acquisition at this point,

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not create competition issues and can go ahead, according to the European Commission.

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory conditions to buy the U.